Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

BACKGROUND: The bevacizumab and irinotecan protocol is considered a standard treatment regimen for recurrent malignant glioma. Recent advances in immunotherapy have hinted that vaccination with dendritic cells could become an alternative salvage therapy for the treatment of recurrent malignant gliom...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Onco Targets Ther
Glavni autori: Artene, Stefan-Alexandru, Turcu-Stiolica, Adina, Hartley, Richard, Ciurea, Marius Eugen, Daianu, Oana, Brindusa, Corina, Alexandru, Oana, Tataranu, Ligia Gabriela, Purcaru, Stefana Oana, Dricu, Anica
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2016
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5108618/
https://ncbi.nlm.nih.gov/pubmed/27877052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S112842
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items